HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Increased endometrial cancer incidence prompts calls for more screening, research funding
-
- Does increased endometrial cancer incidence warrant more intensive screening?
- Cancer clinical trials: Not suitable for prime time John Sweetenham, MD, FRCP, FACP
- Bidirectional immuno-oncology educational program benefits community practices
- Black men achieve deeper response to abiraterone acetate for advanced prostate cancer
- Bevacizumab plus chemotherapy prolongs PFS for recurrent ovarian cancer
- Collaborative investment may expedite drug development for pediatric cancer
- Adjuvant FOLFIRINOX new standard of care for pancreatic cancer
- Adjuvant docetaxel shows benefit for gastric cancer
-
- Novel nivolumab combination shows efficacy for advanced solid tumors
- Benefit of first-line alectinib persists over crizotinib for ALK-positive lung cancer
- First-line atezolizumab improves PFS for advanced squamous non-small cell lung cancer
- Geriatric assessment improves oncologists’ communication with older patients
- CAR T-cell therapy bb2121 shows sustained promise for multiple myeloma
- CAR T-cell therapy benefit for pediatric leukemia dependent on prompt treatment
- Ibrutinib plus rituximab improves PFS in Waldenström’s macroglobulinemia
- Nelarabine shows ‘best ever survival data’ for children, young adults with T-cell ALL
-
- Long-term treatment-free remission achievable for chronic myeloid leukemia
- Targeted inhibitor induces responses for soft tissue sarcoma
- Cognitive behavioral therapy, acupuncture reduce insomnia among cancer survivors
- FDA commissioner: Greater efficiencies can unlock opportunities created by better science
- Cytoreductive nephrectomy no longer the standard for metastatic renal cell carcinoma
- Germline variant alleles may predict response to first-line abiraterone for metastatic prostate cancer
- Neoadjuvant pembrolizumab induces pathologic response in bladder cancer
- PET response after induction chemotherapy may predict esophageal cancer outcomes
-
- Cancer increases risk for subsequent diabetes
- US cancer deaths continue to decline
- Multigene sequencing replaces BRCA testing after breast cancer diagnosis
- Mortality risk greater for male transfusion recipients with previously pregnant donor
- Higher vitamin D levels associated with lower colorectal cancer risk for women
- FDA grants fast track designation to fimepinostat for lymphoma subtype
- FDA approves Fulphila, first Neulasta biosimilar, to prevent infection during cancer treatment
- FDA grants priority review to Hemlibra for hemophilia A without factor VIII inhibitors
-
- FDA grants priority review to larotrectinib for certain solid tumors
- FDA grants priority review to Promacta for frontline treatment of severe aplastic anemia
- FDA breakthrough therapy designation not associated with improved safety, efficacy
- 11 institutions join AACR Project GENIE Consortium
- Radiation oncologist to serve as American Radium Society’s president-elect